<SEC-DOCUMENT>0001144204-19-037255.txt : 20190801
<SEC-HEADER>0001144204-19-037255.hdr.sgml : 20190801
<ACCEPTANCE-DATETIME>20190801171527
ACCESSION NUMBER:		0001144204-19-037255
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20190801
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Regulation FD Disclosure
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20190801
DATE AS OF CHANGE:		20190801

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PHIBRO ANIMAL HEALTH CORP
		CENTRAL INDEX KEY:			0001069899
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				131840497
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36410
		FILM NUMBER:		19993595

	BUSINESS ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666
		BUSINESS PHONE:		201-329-7300

	MAIL ADDRESS:	
		STREET 1:		GLENPOINTE CENTRE EAST, 3RD FLOOR
		STREET 2:		300 FRANK W. BURR BLVD., SUITE 21
		CITY:			TEANECK
		STATE:			NJ
		ZIP:			07666

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PHILIPP BROTHERS CHEMICALS INC
		DATE OF NAME CHANGE:	19980908
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tv526497_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 12pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>UNITED
STATES</B><BR>
<B>SECURITIES AND EXCHANGE COMMISSION</B></FONT><BR>
<B>WASHINGTON, DC 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;<B>&nbsp;</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>FORM 8-K</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>CURRENT REPORT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PURSUANT TO SECTION 13 OR 15(d) OF THE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SECURITIES EXCHANGE ACT OF 1934</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of report (Date of earliest event reported):
August 1, 2019</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Phibro Animal Health Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact name of registrant as specified in
its charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>01-36410</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>13-1840497</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of<BR>
incorporation)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(Commission File Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt">(IRS Employer Identification No.)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 42%; padding-right: 5.4pt; padding-left: 5.4pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Glenpointe Centre East, 3rd Floor</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>300 Frank W. Burr Boulevard, Suite 21</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Teaneck, New Jersey</B></P></TD>
    <TD STYLE="width: 16%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 42%; text-align: center"><FONT STYLE="font-size: 10pt"><B>07666-6712</B></FONT></TD></TR>
<TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Address of Principal Executive Offices)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Zip Code)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Registrant&rsquo;s telephone number, including
area code: <B>(201) 329-7300</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Not Applicable</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Former name or former address, if changed
since last report)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;Securities registered pursuant
to Section 12(b) of the Act:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Title of each class</U></B></FONT></TD>
    <TD STYLE="width: 20%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Trading Symbol(s)</U></B></FONT></TD>
    <TD STYLE="width: 40%; padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B><U>Name of each exchange on which registered</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Class A Common Stock, $0.0001 par value per share</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>PAHC</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 2.2pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>NASDAQ Stock Market</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if this
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))</TD>
</TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.25in; text-align: left"><FONT STYLE="font-family: Wingdings">&#168;</FONT></TD><TD STYLE="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Indicate by check mark whether the
registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &sect;230.405) or Rule 12b-2
of the Securities Exchange Act of 1934 (17 CFR &sect;240.12b-2).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">Emerging growth company <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <FONT STYLE="font-family: Wingdings">&#168;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Item 1.01.&nbsp; Entry Into a Material Definitive Agreement.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">On August 1, 2019 (the
&ldquo;<B><I>Closing Date</I></B>&rdquo;), Phibro Animal Health Corporation, a Delaware corporation (&ldquo;<B><I>Phibro</I></B>&rdquo;),
entered into an Asset Purchase Agreement (the &ldquo;<B><I>Agreement</I></B>&rdquo;) among Phibro, Osprey Biotechnics, Inc., a
Florida corporation (&ldquo;<B><I>Seller</I></B>&rdquo;), Lauren Danielson (&ldquo;<B><I>Danielson</I></B>&rdquo;) and Vincent
Scuilla (&ldquo;<B><I>Scuilla</I></B>&rdquo; and, together with Danielson and Seller, the &ldquo;<B><I>Selling Parties</I></B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-size: 10pt">Seller
develops, manufactures and markets microbial products and bioproducts for a variety of applications serving animal health and nutrition,
environmental, industrial and agricultural customers (the &ldquo;<B><I>Osprey Business</I></B>&rdquo;). Seller</FONT> also <FONT STYLE="font-size: 10pt">produces
key components for Phibro&rsquo;s recently launched Provia Prime&trade; direct fed microbial product for poultry.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the terms
of the Agreement, Phibro acquired from the Selling Parties all of the assets and business operations relating to the Osprey Business,
including all intellectual property, working capital and property, plant and equipment, for an aggregate purchase price of Fifty
Five Million Dollars ($55,000,000), subject to working capital and certain other price adjustments (the &ldquo;<B><I>Purchase Price</I></B>&rdquo;).
In addition to the Purchase Price, the Agreement provides that Phibro shall pay to Seller an earn-out payment in an amount equal
to the earnings before interest, taxes, depreciation and amortization of the Osprey Business for the twelve month period ending
on June 30, 2021, multiplied by one hundred ten percent (110%); provided, however, that the earn-out payment shall be no less than
Four Million Eight Hundred Forty Thousand Dollars ($4,840,000), subject to withholding for indemnification claims.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Purchase Price
was paid in cash at the Closing Date. Phibro funded the acquisition through its existing credit facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Agreement contains
customary representations, warranties and covenants by Phibro and the Selling Parties and customary indemnification provisions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">This description of
the Agreement is a summary only and is qualified in its entirety by the full and complete terms of the Agreement.&nbsp; Phibro
expects to file the Agreement as an exhibit to its quarterly report on Form&nbsp;10-Q for the period ending September 30, 2019.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>Item 7.01. Regulation FD Disclosure.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On August 1, 2019, the Company issued a
press release announcing the acquisition. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form
8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The information contained in this press
release is being furnished and shall not be deemed to be &ldquo;filed&rdquo; for purposes of Section 18 of, or otherwise regarded
as filed under, the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), nor shall it be deemed incorporated
by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>(d) &nbsp;Exhibits</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Exhibit Number</B></FONT></TD>
    <TD STYLE="width: 2%; padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="width: 78%; border-bottom: Black 1pt solid; padding: 0; text-align: justify; text-indent: 0"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding-top: 0; padding-right: 0; padding-left: 0; text-align: justify; text-indent: 0">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><A HREF="tv526497_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">99.1</FONT></A></TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0">&nbsp;</TD>
    <TD STYLE="padding: 0; text-align: justify; text-indent: 0"><A HREF="tv526497_ex99-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Press Release, dated August 1, 2019</FONT></A></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>SIGNATURES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;Date: August 1, 2019</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">PHIBRO ANIMAL HEALTH CORPORATION</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 35%; border-bottom: black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Thomas G. Dagger</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;<BR>
Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Thomas G. Dagger<BR>
Senior Vice President, General Counsel <BR>
and Corporate Secretary</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;&nbsp;</P>

<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>tv526497_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="image_001.jpg" ALT=""></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Phibro Animal Health Corporation Acquires
Business of Osprey Biotechnics, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">TEANECK, N.J., August 1, 2019 (Business Wire)
&ndash; Phibro Animal Health Corporation (&ldquo;Phibro&rdquo;) (NASDAQ:PAHC) today announced it has acquired the business and
assets of Osprey Biotechnics, Inc. (&ldquo;Osprey&rdquo;), a privately held developer and marketer of innovative microbial products.
Acquiring the Osprey business strengthens Phibro&rsquo;s portfolio of nutritional specialty products and provides new opportunities
in a fast-growing sector of the animal health industry. Osprey manufacturers and markets numerous products for a variety of applications
and industries. Osprey also produces the key components for Phibro&rsquo;s recently launched Provia Prime&trade; direct fed microbial
product for poultry.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;Osprey is a great business run by people
we deeply respect. This acquisition provides Phibro with new product opportunities and a cutting-edge organization with strong
manufacturing capabilities,&rdquo; said Jack Bendheim, Phibro&rsquo;s Chairman, President and Chief Executive Officer. &ldquo;Osprey&rsquo;s
proven and ever-expanding library of microbial strains will serve as an excellent platform for growth within the animal health
industry as well as in burgeoning agriculture adjacencies such as seed coatings.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;We are excited to join the Phibro family,&rdquo;
said Lauren Danielson, Chief Executive Officer of Osprey. &ldquo;Partnering with Phibro opens up even more opportunities for our
business, as it allows us to leverage Phibro&rsquo;s proven expertise in nutritional specialty products that help improve animal
health, productivity and profitability. We are also excited about the ability to scale our fermentation capacity, utilizing Phibro&rsquo;s
current footprint, to further service our customers. The value of this transaction is a testament to the highly skilled, innovative
and hard-working people of Osprey.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&ldquo;We welcome Osprey&rsquo;s dedicated
team of employees to Phibro, and we are thrilled that Osprey&rsquo;s leadership of Lauren Danielson and Vince Scuilla will continue
as leaders of our microbial business as we integrate Osprey into Phibro,&rdquo; said Larry Miller, Phibro&rsquo;s Chief Operating
Officer. &ldquo;Our employees share similar values and have a shared vision for working collaboratively with customers to help
identify and provide solutions. We value the longstanding strategic relationships Osprey has built with its many customers across
multiple industries, and we look forward to continuing to develop and strengthen these partnerships.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Phibro expects the transaction to be accretive
to adjusted EBITDA and adjusted diluted EPS for the fiscal year ending June 30, 2020. Phibro funded the acquisition through its
existing credit facilities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>&nbsp;&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>About Phibro Animal Health Corporation</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Phibro Animal Health Corporation is a diversified
global developer, manufacturer and supplier of a broad range of animal health and mineral nutrition products for livestock, helping
veterinarians and farmers produce healthy, affordable food while using fewer natural resources. For further information, please
visit www.pahc.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Contact:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Phibro Animal Health Corporation</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Richard Johnson</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Chief Financial Officer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">+1-201-329-7300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">investor.relations@pahc.com</P>



<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V *8# 2(  A$! Q$!_\0
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MP?7-/ZK+$ITXD5$G&S+?V#Q#_P \+[_OEJ/L'B'_ )X7W_?+5SO_  O'6O\
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E$0V70]9FFDC75'BM"Y>.-+B0%<!5 )],#\R:***^CYV=]C__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
